Immunotech Biopharm to Issue New Convertible Bonds to Settle 2023 Notes

Immunotech Biopharm Ltd ( (HK:6978) ) just unveiled an update.

Immunotech Biopharm Ltd has entered into a subscription agreement with an investor to issue new convertible bonds totaling RMB270 million at an initial conversion price of HK$2.92 per share, along with a RMB30 million note, both secured under existing security arrangements. The issuance, under the company’s general mandate and not requiring separate shareholder approval, could result in up to 102.88 million new shares, representing about 14.28% of the enlarged share capital, if fully converted.

The proceeds from the new convertible bonds and the note will be used exclusively to fully settle the principal of the company’s 2023 convertible bonds maturing on 20 February 2026, with outstanding interest to be paid in cash. Completion of the subscription remains subject to conditions precedent and may not proceed, leaving shareholders and investors cautioned about execution risk as the company seeks to refinance and tidy up its balance sheet through this debt-for-debt settlement.

The most recent analyst rating on (HK:6978) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Immunotech Biopharm Ltd stock, see the HK:6978 Stock Forecast page.

More about Immunotech Biopharm Ltd

Immunotech Biopharm Ltd is a Hong Kong-listed biopharmaceutical company focused on developing and commercializing innovative therapies, with financing activities supported through equity-linked instruments. The company taps capital markets via convertible bonds and share issuance to fund its operations and manage existing obligations within the healthcare sector.

Average Trading Volume: 922,698

Technical Sentiment Signal: Sell

Current Market Cap: HK$1.56B

For a thorough assessment of 6978 stock, go to TipRanks’ Stock Analysis page.